Results of a randomized, double‐blind, parallel‐group, placebo‐ and active‐controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia

Kuo, Hann‐Chorng; Lee, Kyu‐Sung; Na, Yan-qun; Sood, Rajeev; Nakaji, Shigeru; Kubota, Yosuke; Kuroishi, Kentarou

doi:10.1002/nau.22645

Cited by 89 publications

(86 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mirabegron, which is a β3-adrenoceptor agonist, has effects on urgency, urinary incontinence and frequency , Kuo et al, 2014 in patients with the overactive bladder syndrome (OAB). Those studies did however not specifically analyze the effect of mirabegron in patients with BOO.…”

Section: Discussionmentioning

confidence: 99%

“…Angiotensin II receptors, on the other hand, are downregulated, and this is of possible relevance for urinary tract dysfunction in rats with 4 BOO (Yamada et al, 2009). Accordingly, current therapies for lower urinary tract symptoms target membrane receptors, including M3 muscarinic receptors (Andersson 2001) and β3-adrenergic receptors , Kuo et al, 2014. Our knowledge regarding effects of BOO on membrane receptor expression is still limited however, and an unbiased survey of receptor expression in BOO may disclose novel targets for therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Non-uniform changes in membrane receptors in the rat urinary bladder following outlet obstruction

Zeng

Ekman

Jiang

et al. 2015

European Journal of Pharmacology

View full text Add to dashboard Cite

The aim of the present study was to investigate the expression and distribution of membrane receptors after bladder outlet obstruction (BOO). Partial bladder outlet obstruction (BOO) was induced in female rats and bladders were harvested after either 10 days or 6 weeks of BOO. The expression of different receptors was surveyed by microarrays and corroborated by immunohistochemistry and western blotting. A microarray experiment identified 10 membrane receptors that were differentially expressed compared to sham-operated rats including both upregulated and downregulated receptors. Four of these were selected for functional experiments on the basis of magnitude of change and relevance to bladder physiology. At 6 weeks of BOO, maximal contraction was reduced for neuromedin B and vasopressin (AVP), consistent with reductions of receptor mRNA levels. Glycine receptor-induced contraction on the other hand was increased and receptor mRNA expression was accordingly upregulated. Maximal relaxation by the β3-adrenergic receptor agonist CL316243 was reduced as was the receptor mRNA level.Immunohistochemistry supported reduced expression of neuromedin B receptors, V1a receptors and β3-adrenergic receptors, but glycine receptor expression appeared unchanged. Western blotting confirmed repression of V1a receptors and induction of glycine receptors in BOO.mRNA for vasopressin was detectable in the bladder, suggesting local AVP production. We conclude that changes in receptor expression following bladder outlet obstruction are nonuniform. Some receptors are upregulated, conferring increased responsiveness to agonist, whereas others are downregulated, leading to decreased agonist-induced responses. This study might help to select pharmacological agents that are effective in modulating lower urinary tract symptoms in BOO.3

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Non-uniform changes in membrane receptors in the rat urinary bladder following outlet obstruction

Zeng

Ekman

Jiang

et al. 2015

European Journal of Pharmacology

View full text Add to dashboard Cite

show abstract

“…In addition to these studies, mirabegron 50 mg/day was shown to be efficacious in patients with overactive bladder syndrome in large (n [ 1000) placebo-and active treatment-controlled trials conducted in Japan [16] and Taiwan, Korea, China and India [17].…”

Section: For Whom Is Mirabegron Indicated?mentioning

confidence: 98%

Mirabegron: a guide to its use in overactive bladder syndrome in the EU

Sanford

Lyseng‐Williamson

2015

Drugs Ther Perspect

View full text Add to dashboard Cite

Mirabegron (Betmiga TM ), a b 3 -adrenergic receptor agonist, is a useful option for the treatment of overactive bladder syndrome. In clinical trials in this patient population, oral mirabegron 50 mg once daily significantly reduced incontinence and micturition episodes, consistently reduced urgency episodes and increased the volume of urine voided per micturition, and was associated with improvements in health-related quality of life and treatment satisfaction. Mirabegron is generally well tolerated and is associated with less dry mouth than extendedrelease tolterodine.Adis evaluation of mirabegron 50 mg/day in overactive bladder syndrome Reduces incontinence, micturition and urgency episodes and increases the volume of urine voided per micturition Improves health-related quality of life and treatment satisfaction Generally well tolerated in adults with overactive bladder syndrome, including those aged C65 and C75 years

show abstract

“…Mirabegron is the first β3 agonist to be used in clinical practice. [50][51][52][53] (D) To assess the efficacy and tolerability of this drug therapy in the treatment of idiopathic overactive bladder (IOAB), two phase II 54,55 (B) and six phase III [56][57][58][59][60][61] (A) randomized clinical trials (RCTs) recruited more than 10,500 adult patients. Of these, seven were randomized, double-blind and placebo-controlled with follow-up of four (one study) and 12 (six studies) weeks, and one was non-placebo-controlled (vs. tolterodine) with 12-month follow-up.…”

Section: Tolterodine Tartratementioning

confidence: 99%

Overactive bladder: pharmacological treatment

Sacomani

Almeida

Silvinato

et al. 2017

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field in order to standardize procedures to assist the reasoning and decision-making of doctors. The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical status of each patient.

show abstract

Results of a randomized, double‐blind, parallel‐group, placebo‐ and active‐controlled, multicenter study of mirabegron, a β3‐adrenoceptor agonist, in patients with overactive bladder in Asia

Abstract: Mirabegron 50 mg once daily for 12 weeks was superior to placebo in reducing the frequency of micturitions in patients with symptoms of OAB in Taiwan, Korea, China, and India.

Cited by 89 publications

References 25 publications

Non-uniform changes in membrane receptors in the rat urinary bladder following outlet obstruction

Non-uniform changes in membrane receptors in the rat urinary bladder following outlet obstruction

Mirabegron: a guide to its use in overactive bladder syndrome in the EU

Overactive bladder: pharmacological treatment

Contact Info

Product

Resources

About